Premium
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis
Author(s) -
Strober B.E.,
Langley R.G.B.,
Menter A.,
Magid M.,
Porter B.,
Fox T.,
Safi J.,
Papavassilis C.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16051
Subject(s) - secukinumab , suicidal ideation , psoriasis , medicine , depression (economics) , adverse effect , anxiety , psychiatry , poison control , dermatology , suicide prevention , environmental health , psoriatic arthritis , macroeconomics , economics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom